<DOC>
	<DOCNO>NCT01664845</DOCNO>
	<brief_summary>The aim study investigate treatment response metformin , Peg-IFN ribavirin combination therapy chronic hepatitis C virus ( HCV ) .</brief_summary>
	<brief_title>Effects Metformin , Pegylated Interferon Alpha Ribavirin Chronic Hepatitis C With Insulin Resistance</brief_title>
	<detailed_description>Current standard treatment HCV pegylated interferon ( Peg-IFN ) -alpha ribavirin achieve sustain virological response ( SVR ) 60-90 % patient . Insulin resistance important factor non-response combination therapy . Metformin insulin sensitizer effectively reduce insulin resistance . The aim study investigate treatment response metformin , Peg-IFN ribavirin combination therapy chronic HCV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV RNA ( + ) ALT &gt; 40 U/L Compensated liver HOMAIR &gt; 2 neutrophil ï¼œ1500/mm3 male : Hb &lt; 13 g/dl , female : Hb &lt; 12 g/dl platelet &lt; 80,000 /mm3 Cr &gt; 2.5 mg/dl Alcohol use &gt; 20 gm per day uncontrolled depression , thyroid disease , autoimmune disease Pregnancy Hepatocellular carcinoma allergy interferon ribavirin Diabetes HBV/HIV coinfection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>hepatitis c</keyword>
	<keyword>metformin</keyword>
	<keyword>pegylated interferon</keyword>
</DOC>